esketamine spravato - Search News

Ketamine Nasal Spray Approved

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Times Now on MSN · 7h

What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a standalone treatment for major depressive disorder or MDD.

HealthDay on MSN · 3h

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,

Hosted on MSN13h

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

17h

J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results